NR 536 Week 5 Develop an Evolving Case Study

Student Name

Chamberlain University

NR-536: Advanced Health Assessment, Pathophysiology & Pharmacology for Advanced Nursing Practice

Prof. Name

Date

NR 536 Week 5 Develop an Evolving Case Study

Overview of the Evolving Case Study

The purpose of this evolving case study is to design a structured treatment plan focused on preventing and managing ventilator-associated pneumonia (VAP) in intensive care units (ICUs). VAP remains one of the most significant complications among mechanically ventilated patients, often leading to increased morbidity, length of hospital stay, and healthcare costs. This case study targets nursing professionals with at least three years of ICU experience, as their clinical judgment and advanced skills are vital in patient outcomes.

Key elements of the study include patient safety, infection prevention, and the use of evidence-based strategies for VAP management. Among these strategies are oral hygiene interventions (Hua et al., 2016), antibiotic stewardship programs to address resistance (Khan et al., 2017), careful sedation management, and ongoing patient assessments (Álvarez-Lerma et al., 2018). Furthermore, physiotherapy techniques (Zampieri et al., 2015) and appropriate device handling are emphasized to enhance patient recovery while minimizing complications.

Case Study Setting

The clinical scenario is set in the ICU of an acute care hospital where a patient with respiratory failure is intubated and supported with mechanical ventilation. The patient is under continuous sedation, receiving IV anticoagulants, IV fluids, and continuous hemodynamic monitoring. Devices in use include pulmonary and cardiac monitors, a vital signs machine, and wall suction for secretion management. This setting reflects the high-risk environment where vigilant nursing care is essential to prevent VAP.

Patient Profile

Patient Information:

• Name: Mr. XYZ
• Gender/Age/Weight/Height: Male, 65 years old, 252 lbs, 5’10”
• Allergies: Codeine
• Past Medical History: Diabetes mellitus, asthma, ischemic stroke (Dec 2019), paroxysmal atrial fibrillation, coronary artery bypass graft (2016), 40-pack-year smoking history, and chronic alcohol use.
• Present Illness: Admitted on February 8, 2020, with complaints of tachypnea, dyspnea, and chest pain. Developed acute respiratory distress requiring intubation in the emergency department.
• Social History: Retired software engineer, lives with spouse, has two adult children living out of state.
• Primary Medical Diagnosis: Pulmonary embolism complicated by pleural effusion, acute respiratory failure, and hypoxemia.
• Surgeries and Procedures: CT scan, chest X-ray, COVID-19 test, blood/urine cultures, arterial blood gas (ABG) testing, serial EKGs, and routine laboratory work.

Evolving Case Study Information and Learning Objectives

Evolving Case Stage	Case Study Information Presented to Learners	Learner Actions	Socratic Questions
Stage One	The patient demonstrates declining oxygenation, requiring higher FiO2/PEEP adjustments. Tachycardia is also present (Hellyer et al., 2016).	– Review medical history – Notify physician – Assess patient – Initiate respiratory support strategies	– What factors may contribute to oxygen desaturation? – Should additional diagnostics (cultures, imaging) be considered? – Is early administration of broad-spectrum antibiotics appropriate?
Stage Two	Patient develops copious purulent secretions, needs frequent suctioning, and shows worsening hypoxemia, leading to activation of VAP prevention protocols.	– Implement VAP prevention bundle – Provide oral hygiene care – Elevate head of the bed (30–45°) – Regulate sedation – Monitor endotracheal tube cuff pressure	– How does oral care contribute to lowering VAP risk? – Is head elevation effective in secretion management? – Could chlorhexidine alternatives be more effective?
Stage Three	VAP diagnosis is confirmed via tracheal aspirate cultures and imaging. Infection shows progression.	– Narrow antibiotic coverage based on culture sensitivity – Reassess patient within 24–48 hours – Initiate spontaneous breathing trials – Consider probiotics – Maintain continuous monitoring	– Do sedation management and breathing trials help reduce VAP incidence? – Is narrowing antibiotics after culture confirmation the optimal approach? – What role could probiotics play in preventing further infection?

Debriefing

Stage 1 Focus

Question: What preventive measures are most effective in reducing VAP among patients with chronic illnesses?
Answer: Preventive strategies include elevating the head of the bed, minimizing sedation, and initiating early mobility protocols. Evidence also supports consistent oral hygiene and minimizing invasive device use when possible (Fortaleza et al., 2020).

Stage 2 Focus

Question: Should VAP bundle components, such as head elevation and oral care, be applied more frequently than once daily?
Answer: Yes. Evidence indicates that oral hygiene, especially when performed multiple times per day with antiseptic solutions, significantly reduces bacterial colonization and lowers infection risk (Prasad et al., 2019). Similarly, consistent head elevation minimizes aspiration and secretion pooling.

Stage 3 Focus

Question: How can bacterial growth in the lungs and trachea be controlled promptly?
Answer: Timely initiation of targeted antibiotics, combined with non-pharmacological interventions such as lung recruitment maneuvers, physiotherapy, and early weaning strategies, is essential. Probiotic therapy also shows promise in reducing colonization of harmful pathogens (Zhao et al., 2020).

Overall Case Study Focus

Question: What comprehensive methods ensure VAP prevention and management in immobilized, mechanically ventilated patients?
Answer: A multidisciplinary approach is most effective. This includes strict adherence to VAP prevention bundles, appropriate sedation management, oral hygiene with antiseptics, spontaneous awakening and breathing trials, and antibiotic stewardship to prevent resistance. Integrating physiotherapy and advanced nursing interventions further enhances patient safety and recovery.

References

Álvarez-Lerma, F., Palomar-Martínez, M., Sánchez-García, M., Martínez-Alonso, M., Álvarez-Rodríguez, J., & Lorente, L. et al. (2018). Prevention of ventilator-associated pneumonia. Critical Care Medicine, 46(2), 181–188. https://doi.org/10.1097/ccm.0000000000002736

Bardia, A., Blitz, D., Dai, F., Hersey, D., Jinadasa, S., Tickoo, M., & Schonberger, R. (2019). Preoperative chlorhexidine mouthwash to reduce pneumonia after cardiac surgery: A systematic review and meta-analysis. The Journal of Thoracic and Cardiovascular Surgery, 158(4), 1094–1100. https://doi.org/10.1016/j.jtcvs.2019.01.014

Fortaleza, C., Filho, S., Silva, M., Queiroz, S., & Cavalcante, R. (2020). Sustained reduction of healthcare-associated infections after the introduction of a bundle for prevention of ventilator-associated pneumonia in medical-surgical intensive care units. The Brazilian Journal of Infectious Diseases, 24(5), 373–379. https://doi.org/10.1016/j.bjid.2020.08.004

Hellyer, T., Ewan, V., Wilson, P., & Simpson, A. (2016). The intensive care society recommended bundle of interventions for the prevention of ventilator-associated pneumonia. Journal of the Intensive Care Society, 17(3), 238–243. https://doi.org/10.1177/1751143716644461

NR 536 Week 5 Develop an Evolving Case Study

Hua, F., Xie, H., Worthington, H., Furness, S., Zhang, Q., & Li, C. (2016). Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008367.pub3

Khan, Z., Ceriana, P., & Donner, C. (2017). Ventilator-associated pneumonia or ventilator-induced pneumonia. Multidisciplinary Respiratory Medicine, 12, 224. https://doi.org/10.4081/mrm.2017.224

Olanipekun, T., & Snyder, R. (2019). Mortality risk in ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Critical Care Medicine, 47(10), e851–e852. https://doi.org/10.1097/ccm.0000000000003662

Pinho, R., Tanure, L., Pessoa, J., Santos, L., Couto, B., & Starling, C. (2020). Impact of each component of a ventilator bundle on preventing ventilator-associated pneumonia and lower respiratory infection. Infection Control & Hospital Epidemiology, 41(S1), S259–S260. https://doi.org/10.1017/ice.2020.824

Prasad, R., Daly, B., & Manley, G. (2019). The impact of 0.2% chlorhexidine gel on oral health and the incidence of pneumonia amongst adults with profound complex neurodisability. Special Care in Dentistry, 39(5), 524–532. https://doi.org/10.1111/scd.12414

Vieira, P., de Oliveira, R., & da Silva Mendonça, T. (2020). Should oral chlorhexidine remain in ventilator-associated pneumonia prevention bundles? Medicina Intensiva. https://doi.org/10.1016/j.medin.2020.09.009

Xie, X., Lyu, J., Hussain, F., & Li, M. (2019). Drug prevention and control of ventilator-associated pneumonia. Frontiers in Pharmacology, 10, 298. https://doi.org/10.3389/fphar.2019.00298

Zampieri, F., Nassar Jr, A., Gusmao-Flores, D., Taniguchi, L., Torres, A., & Ranzani, O. (2015). Nebulized antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis. Critical Care, 19(1), 150. https://doi.org/10.1186/s13054-015-0868-y

Zhao, J., Li, L., Chen, C., Zhang, G., Cui, W., & Tian, B. (2020). Do probiotics help prevent ventilator-associated pneumonia in the critically ill patients? A systematic review with meta-analysis. ERJ Open Research. https://doi.org/10.1183/23120541.00302-2020